Black Diamond Therapeutics Inc’s recently made public that its 10% Owner BIOTECH GROWTH N V acquired Company’s shares for reported $0.93 million on Oct 17 ’23. In the deal valued at $2.34 per share,400,000 shares were bought. As a result of this transaction, BIOTECH GROWTH N V now holds 8,517,839 shares worth roughly $45.66 million.
Then, Behbahani Ali bought 1,000,000 shares, generating $5,000,000 in total proceeds. Upon buying the shares at $5.00, the Director now owns 4,448,757 shares.
Before that, RA CAPITAL MANAGEMENT, L.P. bought 935,850 shares. Black Diamond Therapeutics Inc shares valued at $4,679,250 were divested by the Director at a price of $5.00 per share. As a result of the transaction, RA CAPITAL MANAGEMENT, L.P. now holds 3,213,828 shares, worth roughly $17.23 million.
Piper Sandler initiated its Black Diamond Therapeutics Inc [BDTX] rating to an Overweight in a research note published recently. A number of analysts have revised their coverage, including Stifel’s analysts, who increased its forecast for the stock in late June from “a Hold” to “a Buy”. H.C. Wainwright also remained covering BDTX and has increased its forecast on June 28, 2023 with a “Buy” recommendation from previously “Neutral” rating. Wedbush revised its rating on June 27, 2023. It rated BDTX as “an Outperform” which previously was an “a Neutral”.
Price Performance Review of BDTX
On Tuesday, Black Diamond Therapeutics Inc [NASDAQ:BDTX] saw its stock jump 0.19% to $5.36. Over the last five days, the stock has gained 13.32%. Black Diamond Therapeutics Inc shares have risen nearly 90.75% since the year began. Nevertheless, the stocks have risen 228.83% over the past one year. While a 52-week high of $6.85 was reached on 03/22/24, a 52-week low of $1.43 was recorded on 01/05/24. SMA at 50 days reached $4.61, while 200 days put it at $3.44. A total of 0.45 million shares were traded, compared to the trading of 0.55 million shares in the previous session.
Levels Of Support And Resistance For BDTX Stock
The 24-hour chart illustrates a support level at 5.22, which if violated will result in even more drops to 5.08. On the upside, there is a resistance level at 5.56. A further resistance level may holdings at 5.76. The Relative Strength Index (RSI) on the 14-day chart is 59.78, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.14, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 39.39%. Stochastics %K at 52.78% indicates the stock is a holding.
How much short interest is there in Black Diamond Therapeutics Inc?
A steep rise in short interest was recorded in Black Diamond Therapeutics Inc stocks on Mar 15, 2024, dropping by 70000.0 shares to a total of 1.81 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 1.88 million shares. There was a decline of -3.87%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 5.58% of the overall stock float, the days-to-cover ratio (short ratio) fell to 2.78.
